LEGEND BIOTECH CORPORA

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

03 Jun 2025 07:45:00 By Nasdaq GlobeNewswire

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

22 May 2025 14:15:00 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

19 May 2025 05:00:00 By Nasdaq GlobeNewswire

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

13 May 2025 04:00:00 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

29 Apr 2025 05:00:01 By Nasdaq GlobeNewswire

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

11 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

25 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

19 Dec 2024 05:01:00 By Nasdaq GlobeNewswire

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

09 Dec 2024 16:35:00 By Nasdaq GlobeNewswire

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

12 Nov 2024 04:00:01 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

07 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

05 Nov 2024 06:10:00 By Nasdaq GlobeNewswire

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

04 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

24 Oct 2024 05:00:01 By Nasdaq GlobeNewswire

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

03 Oct 2024 04:30:00 By Nasdaq GlobeNewswire

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

27 Sep 2024 13:35:00 By Nasdaq GlobeNewswire

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

20 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

09 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

08 Aug 2024 13:05:00 By Nasdaq GlobeNewswire

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

26 Jul 2024 04:00:00 By Nasdaq GlobeNewswire